| P2093 | author name string | T Clark Gamblin | |
| | Ghassan K Abou-Alfa | |
| | Zoran Gatalica | |
| | Nelson S Yee | |
| | John T Miura | |
| | Celina Ang | |
| | Joanne Xiu | |
| | Sandeep K Reddy | |
| | Sherri Z Millis | |
| | Ruth He | |
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| | Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 |
| | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 |
| | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| | Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer | Q28298328 |
| | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 |
| | Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status | Q29619648 |
| | Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial | Q33410643 |
| | Gene expression in fixed tissues and outcome in hepatocellular carcinoma. | Q34235518 |
| | Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial | Q34663499 |
| | Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial | Q34786090 |
| | MicroRNA Profiling of Laser-Microdissected Hepatocellular Carcinoma Reveals an Oncogenic Phenotype of the Tumor Capsule | Q35028814 |
| | Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial | Q35168763 |
| | PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models. | Q35228413 |
| | Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative | Q35680026 |
| | Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses | Q35899928 |
| | Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets | Q36104399 |
| | Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma | Q36547263 |
| | MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a | Q36924035 |
| | Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network | Q37404105 |
| | Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial | Q37809940 |
| | Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? | Q37942465 |
| | Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. | Q38062681 |
| | Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning. | Q38176242 |
| | Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets | Q39014708 |
| | Synergistic growth inhibition by 9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells | Q39986318 |
| | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study | Q43691230 |
| | Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. | Q44845388 |
| | An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma. | Q45358181 |
| | Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | Q45980006 |
| | Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. | Q46484712 |
| | Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib | Q46618741 |
| | SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. | Q50454368 |
| | Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers | Q50539670 |
| | DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. | Q51499838 |
| | Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles. | Q51735700 |
| P433 | issue | 1 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 55-61 | |
| P577 | publication date | 2015-12-10 | |
| P1433 | published in | Journal of Surgical Oncology | Q1919535 |
| P1476 | title | Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options | |
| P478 | volume | 113 | |